We also used CFZ to treat other cancer cell types (one renal cell carcinoma and two breast cancer cell lines) and normal cells (CD34+ cells and monocytes), but down-regulation of HLA class I was not observed (data not shown). This evidence concerns the gene CD34 and breast cancer.